Background Animal models are an important tool to understand intestinal biology. Our laboratory previously generated C57BL/6-Tg(Car1-cre)5Flt transgenic mice (CAC) with large-intestine-specific Cre recombinase (Cre) expression as a model to study colon health. Aim To expand the utility of the CAC mouse model by determining the impact of chemically induced colitis on CAC transgene expression. 
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Introduction
Colorectal cancer is a multi-factorial disease, and its development can be influenced by genetics, diet, inflammation, environment, and other factors [1] [2] [3] [4] [5] [6] . Unfortunately, the etiology of colorectal cancer remains unclear; thus, barriers exist to develop approaches to prevent and treat the disease [7] [8] [9] . Controlled animal studies are an important approach to understand colorectal cancer biology and to test promising strategies for disease prevention and treatment. As such, an optimal animal model of colorectal cancer should capture the pathological changes, molecular mechanisms, and clinical symptoms presented in the human disease. In addition, the cancer effect should be limited to colon to avoid the confounding effect of cancer in other tissues. Many animal models have been developed for colorectal cancer research, and they have been reviewed in several recent comprehensive reviews [10] [11] [12] . Our laboratory previously generated a transgenic mouse model for colorectal cancer research with large-intestine-specific Cre recombinase (Cre) transgene expression, i.e., the C57BL/6-Tg(Car1-cre)5Flt or CAC mouse [13] . In colon epithelial cells of CAC mice, Cre is expressed in approximately 10 % of the epithelium. Here we report that Cre expression in colon epithelial cells of CAC mice can be increased during dextran sulfate sodium (DSS)-induced colitis. In addition, our data suggest that these recombination events induce a persistent effect that can be used to study genes involved in the epithelial response to colitis or in colitis-associated colon cancer.
Materials and Methods
Animals C57BL/6-Tg(Car1-cre)5Flt mice were created by our group [13] and maintained as heterozygotes (CAC Tg/WT ).
The Rosa26R strain, B6.129S4-Gt(ROSA)26Sortm1Sor/J, was obtained from the Jackson Laboratory (Bar Harbor, ME) and maintained as homozygotes (ROSA flox/flox ). Rosa26R mice contain a STOP sequence that is flanked by LoxP sites upstream from the E. coli b-galactosidase (bgal) gene within a gene trap of the Rosa26 allele [14] . The Apc CKO mouse carrying a floxed exon 14 of the Apc gene (Apc CKO/CKO ) was obtained from the Mouse Models of Human Cancer Consortium (National Cancer Institute, Frederick, MD). In cells expressing Cre, exon 14 is removed resulting in a truncated 580 amino acid long protein produced from one (Apc D580/WT ) or both (Apc D580/ D580 ) Apc alleles. Genotypes were determined by standard PCR methods as previously described for the CAC [13] , Rosa26R [14] , and floxed Apc alleles [13] . Each strain of mouse was maintained on a C57BL/6J background. Mice were bred to create experimental animals with specific combinations of genotypes. All mouse breeding colonies were housed individually, given a standard chow diet and water ad libitum, and exposed to a 12-h light/12-h dark cycle. The experiments were conducted with approval from the Purdue University Animal Care and Use Committee. mice. Experimental mice were weaned at 3 weeks of age and fed the AIN93G diet [15] . Mice were randomly assigned into one of four dextran sulfate sodium (DSS) treatment groups (0, 0.65, 1.35, and 2 %, n = 16 per group, 8 male and 8 female). DSS (MW = 36,000-50,000 Da, MP Biomedicals, LLC, Solon, OH) was diluted in deionized water (w/v) to the appropriate concentrations. At 8 weeks of age, mice received the DSS solution in place of water ad libitum for 5 consecutive days. Afterward, DSS was replaced with deionized water and this was provided until the day of killing. Half of the mice in each group were killed 2 days after ending the DSS treatment, and half were killed 10 days after ending the DSS treatment. All mice were fasted overnight before harvest. At necropsy, the proximal and distal colon were prepared as Swiss rolls and examined for b-galactosidase levels by immunohistochemistry.
Experiment 2
24 CAC Tg/WT ;Rosa26R flox/flox mice (12 female and 12 male) were weaned at 3 weeks of age and fed AIN93G diet. At 8 weeks of age, 16 mice (8 male and 8 female) were treated with 1.35 % DSS for 5 days and the other 8 mice (4 male and 4 female) were used as vehicle controls (0 % DSS). Half of the DSS-treated mice and all the vehicle control mice were killed 10 days after completing the DSS treatment. The other mice in the DSS treatment group were killed 30 days after completing the DSS treatment. All mice were fasted overnight before harvest. At necropsy, the proximal and distal colon were prepared as Swiss rolls and examined for b-galactosidase levels by immunohistochemistry. Small intestine, kidney, spleen, liver, and lung were also collected for detection of b-galactosidase enzymatic activity. ;Apc D580/WT mice were treated with either 2 % DSS (n = 38) or deionized water (n = 43) at 10 weeks of age for 5 days; then, the DSS was replaced with water. Mice were killed at 20 weeks of age after an overnight fast. The colon was removed, opened longitudinally, and cleaned with PBS. Digital images were collected and analyzed to determine the number, location, and size of each tumor.
Detection of b-galactosidase Activity in Organs
Tissues were dissected from the mice, rinsed briefly in cold PBS, and fixed for 1-2 h in ice-cold 4 % paraformaldehyde. After rinsing the tissue for 15 min in PBS, tissues were incubated for 4 h in 1 mg/mL 5-bromo-4-chloro-3-indoyl-b-D-galactopyranoside (X-gal; Invitrogen; B-1690) solution (pH 7.6) at 37°C as previously described [13] . In tissues expressing bgal (indicative of Cre-mediated recombination of the Rosa26R locus), the enzyme converted the X-gal substrate into a dark blue crystalline precipitate that is visible upon gross examination.
Tissue Preparation and Immunohistochemical Detection of b-galactosidase
The colon was opened longitudinally, rinsed with cold PBS, and transected at its midpoint to separate the proximal and distal colon. Each section was split longitudinally and Swiss-rolled [16] , resulting in two rolls of proximal colon and two rolls of distal colon per mouse. Tissues were immersion fixed for 48-72 h in 10 % neutral-buffered formalin at 4°C before being transferred to 70 % ethanol. Tissues were processed and embedded in paraffin within 7 days of collection at the Purdue Histology and Phenotyping Laboratory.
Four-micron tissue sections were cut, de-paraffinized, and rehydrated through xylene, ethanol, and water by standard methods. For antigen retrieval, slides were submerged in 0.01 mol/L sodium citrate (pH 6.0) and heated to 96°C for 20 min in a laboratory microwave (PELCO, Edmond, OK). Immunohistochemistry was performed on a Dako Autostainer (Dako, Denmark). Slides were incubated with 0.03 % hydrogen peroxide (5 min) and serum-free protein block (30 min, Dako, Denmark), followed by a 120-min incubation with rabbit polyclonal anti-b-galactosidase (bgal) antibody (1:400 dilution; Novus; NB100-65209). Antigen binding was detected with a horseradish peroxidase-labeled anti-rabbit IgG polymer (Vector laboratories; MP-7410) and 3, 3 0 -diaminobenzidine (DAB; Vector laboratories; SK-4100) as the chromogen. Slides were counterstained with Harris hematoxylin (EK Industries, Juliet, IL). The digital images were collected with an Aperio ScanScope slide scanner (Leica Technologies, Buffalo Grove, IL) at 209 magnification.
Image Analysis
Mucosal transgene expression was determined by quantifying the percent bgal-positive pixels after immunohistochemistry. The colonic mucosa was differentiated from the tunica muscularis using the Genie Histology Pattern Recognition software (Aperio, Leica Biosystem) trained at 59 magnification and 1000 iterations to a mean training accuracy of 96 %. A positive pixel count algorithm was then used to analyze DAB labeling within the mucosa. This analysis was done by a board-certified veterinary pathologist (RLJ) and confirmed independently (by FW).
The area of bgal-positive crypts was determined by manually measuring the length of the mucosal surface containing bgal-labeled crypts. bgal-positive crypts were included only if the entire crypt axis, from base to lumen, was within the plane of section or if the crypt base could be seen immediately adjacent to the muscularis mucosa. The percentage of area represented by bgal-positive crypts was calculated by dividing the length of the bgal-positive area by the total length of the mucosa surface.
The damaged tissue surface area included the areas of ulceration and areas undergoing active healing. Ulceration was defined as sections of the colon mucosa devoid of crypts. This phenotype is obvious at day 2 after DSS termination and increased with DSS dose. Tissue healing included restitution (a single layer of epithelial cells covering an ulcer bed), crypt fission, and crypt regenerationtwo events that repopulate the organized crypt structure within an ulcer. These phenotypes were observed at day 10 after DSS termination and continued through day 30 after DSS termination. The percentage of damaged surface was defined as the length of damaged mucosa divided by the total length of the mucosal surface.
Statistical Analysis
Statistical analysis was performed with SAS Enterprise 5.1 software (SAS Institute, Cary, NC). All data were reported as the mean ± standard error of the mean (SEM). Normality of the data was determined by evaluation of its histogram and a Shapiro-Wilk normality test (p [ 0.05). All of the data were normally distributed. Statistical comparisons were made by two-tailed Student's t tests, oneway ANOVA, or Chi-square test as appropriate. Following one-way ANOVA, the Bonferroni multiple comparison test or planned orthogonal contrasts were used to compare groups. Differences were considered significant at p B 0.05 for all the statistical comparisons. 
Mice
Our group has previously reported that CAC mice have recombination of the Rosa allele that is restricted to the large-intestine epithelial cells [13] . In our experiments, bgal labeling is used as an indicator of Cre-mediated transgene recombination. In experiment 1, we examined the proximal and distal colon of CAC Tg/WT ;Rosa26R flox/ WT ;Apc D580/WT mice without DSS treatment ( Fig. 1a-d) . The proximal colon under the basal, non-DSS condition had significantly more bgal-positive cells than the distal colon (Fig. 1e , p = 0.0023). However, bgal labeling in proximal colon was mostly superficial, while entire crypts were labeled in distal colon (Fig. 1b, d) . As a result, fivefold more bgal-positive crypts were observed in the distal colon than the proximal colon (Fig. 1f , p = 0.0011).
Ten days after DSS treatment, bgal labeling was significantly increased at all three DSS doses (Fig. 2a , vehicle versus DSS, proximal colon: p \ 0.0001; distal colon: p = 0.0007). In both the proximal colon and distal colon, a significant increase in bgal labeling was observed as more DSS was used, although the labeling plateaued in the 2 % DSS treatment group (Fig. 2a) . In addition, the increased bgal labeling was present from the surface to the crypt base in both colonic segments (Fig. 3) . The impact of DSS treatment on bgal activity was also examined in the small intestine, liver, spleen, lung, and kidney. As reported previously [13] , bgal activity was not observed in the small intestine, even after DSS induction (data not shown). Both liver and lung had low-level baseline transgene recombination but this was not increased by DSS treatment. Kidney had non-specific bgal activity in non-transgenic mice, but this did not increase in either the CAC mouse or the CAC mouse treated with DSS. In the spleen, there was no transgene expression either at baseline or after DSS treatment (Supplemental Fig. S1 ).
As expected, the percentage of damaged epithelial surface was higher with increasing DSS dose in both proximal colon and distal colon (Fig. 2b) . In addition, there was a direct, positive correlation between epithelial damage and bgal expression in both colonic segments (r 2 C 0.9, slope = 0.75, Fig. 2c ). Also, regardless of the DSS dose, approximately 60 % of the abnormal crypts in the areas of epithelial damage were bgal positive (data not shown). This indicates that Cremediated recombination of the lacZ locus has occurred in the epithelium that expanded to heal the DSS-induced ulcers.
Increased bgal Expression Resulting from DSSInduced Colon Damage Is Sustained After Tissue Recovery
In normal colon mucosa, the crypts are well organized and separated by very little lamina propria (Fig. 4a, b) . Ten days after DSS treatment, the ulcerated mucosa was undergoing active healing, characterized by epithelial restitution, crypt fission, and crypt regeneration (Fig. 4c,  d ). By 30 days after DSS treatment, the ulcerated mucosa was filled with normal-appearing crypts that were separated by slightly increased amounts of lamina propria (Fig. 4e, f) . As we observed in the first study, the total percentage of bgal-positive crypts was significantly higher in the DSS treatment groups than in the vehicle controls at 10 day post-DSS (proximal colon in Fig. 5a , p \ 0.0001, distal colon in Fig. 5d , p = 0.0024) and greater than 60 % of the crypts in the healing ulcer were bgal positive (Fig. 5b, e) . This increased bgal staining remained 30 days after termination of DSS treatment (Fig. 4, Supplemental  Fig. S2, Fig. 5 ). In fact, the percentage of bgal-positive crypts in the healing/healed ulcer was higher at 30 day post-DSS than at 10 day post-DSS (e.g., 75.2 ± 4.4 vs 57.9 ± 6.3 % in proximal colon). The DSS treatment group also had significantly more bgal-positive crypts in areas of normal-appearing crypts that were adjacent to healing mucosa (Fig. 5c , f, proximal colon: p \ 0.0001; distal colon: p = 0.0001). This indicated that the transgene expression induced by DSS was sustained in the tissue after recovery of the damaged epithelium.
DSS-Induced Transgene Recombination Increases Tumor Formation
We first examined whether bgal staining occurs coincident with adenomatous phenotypes that result from deletion of two floxed Apc alleles. In CAC mice, 30 % of the distal colon exhibited an adenomatous phenotype consistent with recombination of both Apc alleles (i.e., increased cytoplasmic basophilia, increased nuclear to cytoplasmic ratio, loss of nuclear basal polarity, disruption of crypt architecture). While only 2.4 % of crypts in normal mucosa were bgal positive (Fig. 6a) , within the adenomatous regions, 88.8 ± 1.5 % of the epithelial cells were positive for bgal (Fig. 6b) . The co-occurrence of bgal labeling (indicative of recombination at the ROSA26R locus) and the adenomatous phenotype (indicative of recombination of both floxed Apc alleles) suggests that Cremediated recombination of floxed alleles is very efficient.
Since DSS treatment induces Cre-mediated recombination in crypts, we hypothesized that DSS would increase tumor incidence in CAC Tg/WT ;Apc D580/WT mice by expanding the colon-specific inactivation of a single Apc allele, coupled with the well-established tumor-promoting effects of inflammation [17] . In the vehicle-treated group, 18.6 % of the mice had a colonic tumor and the tumors were all in the distal colon (Table 1, 1.25 per mouse). In contrast, DSS treatment significantly increased the percentage of mice with colonic tumors to 78.9 % (DSS vs vehicle, p \ 0.0001) and this included the appearance of tumors in the proximal colon in 34 % of mice. The number of colonic tumors developed per mouse was also significantly higher in the DSS-treated mice compared to the vehicle controls (4.20 vs 1.25 per mouse, p \ 0.0001). The DSS treatment resulted in twice as many mice with tumors in the distal colon compared to the proximal colon (Table 1 , 74 vs 34 %, respectively) and twice as many tumors in the distal versus the proximal colon (Table 1 , 3.71 vs 1.47 per mouse, respectively). Thus, the CAC-mediated recombination of Apc alleles induced by DSS along with the pro-inflammatory environment within DSS-induced ulcers was a potent promoter of colon cancer.
Discussion
Our results expand the utility of the CAC mouse model by demonstrating that recombination of floxed alleles driven by the Cre recombinase transgene is increased during DSS colitis. This effect was restricted to large intestinal epithelial cells, was tightly correlated with DSS-induced epithelial damage, was visible during the healing of ulcers, and persisted in crypts within the healed epithelium. However, since DSS causes colon epithelial damage that is accompanied by local inflammation, it is not clear whether induction of transgene activity is a result of the epithelial damage, healing, inflammation, or the factors combined. While the mechanism for this effect is not known, two lines of evidence suggest that the colonic stem cell has been affected. First, recombination is evident in epithelial ;Apc D580/WT mice. Animals were treated with 2 % DSS for 5 days, and the tissues were collected at 10 days after stopping DSS treatment. Representative images were generated using an Aperio ScanScope digital slide scanner and are presented for proximal colon (a, b) and distal colon (c, d). The top pictures are at 92 magnification, and the bottom pictures are at 920 magnification. Arrow head normal crypt structure adjacent to a healing area. Arrow crypt fission phenotype within a healing area cells from the luminal surface to the crypt base where colon stem cells reside, and second, the effect is persistent in crypts and lasts after the damaged epithelium has healed. Lgr5 ? cells have been identified as rapid turnover intestinal stem cells [18] that maintain the intestinal epithelium [19] .
However, Lgr5
? stem cells are absent from the DSS-damaged areas of the distal colon [20] . Other putative intestinal stem cells with moderate proliferative capacity have been identified including cells marked by Tert, Bmi1, Hopx, and Lrig1
? cells. These stem cells may interconvert to maintain the intestinal epithelium, especially under stress, e.g., as seen when Bmi1
? cells serve as the stem cell reservoir in the small intestine when Lgr5
? cells are deleted [21, 22] . Although Bmi1
? cells are not present in the colon [21] , Lrig1
? cells are found in there [23] . We hypothesize that CAC transgene expression may be activated in Lrig1
? cells during healing and that recombined floxed alleles are retained in Lrig1
? cells which then pass them to new Lgr5
? cells that repopulate the epithelium after ulcer healing.
Further experiments examining transgene expression in Lrig1 ? and Lgr5 ? cells before, during, and after DSS-induced colitis need to be done to test the hypothesis.
In addition to the CAC mouse we developed and used in these experiments [13] , several other mouse models exist for colon research and each have advantages and disadvantages [11] . A 12.4-kb region of the mouse villin promoter drives Cre recombinase expression uniformly throughout the epithelial cells of the intestine [24] . However, villin-Cre transgene expression extends into the small intestine [24] and this can confound interpretation of events occurring in the colon. An improvement on the villin-Cre mouse was accomplished by using a 9-kb villin promoter to drive a CreER T2 transgene that is tamoxifen inducible and which can cause gene deletions that are spatially and temporally controlled. However, 60 days after treating villin-CreER T2 mice with tamoxifen, the persistence of recombination in small intestine was seen in 80 % of the epithelium, while in the colon, it was just 40 % [25] . Moreover, villin promoter-driven Cre or Cre-ER T2 transgene expression level is lower in the crypt base where stem cells are found [24, 25] and this suggests that Cre activity in the colon stem cell compartment may not be sufficient for optimal recombination. Arrow bgal labeling in a normal crypt. b bgal expression in distal colon adenomatous phenotype. Arrow adenomatous phenotype with bgal-positive labeling. Arrow head adenomatous phenotype with bgal-negative labeling. Images were generated using an Aperio ScanScope digital slide scanner magnification 920 Deletion of floxed alleles directly in intestinal stem cells can be accomplished using the Lgr5 promoter-CreER T2 mouse [26] and the Lrig1 promoter-CreER T2 mouse [23] . Unfortunately, inducible Cre-ER T2 transgene activity is very low in the large intestine of Lgr5 promoter-CreER T2 mice [27] and so, like the villin promoter models, the Lgr5 promoter-CreER T2 mouse is best for inducing small intestinal cancer. The Lrig1 promoter-CreER T2 mouse forms multiple adenomas in the distal colon when it is used to delete an Apc allele; however, many tumors are also seen in the small intestine [23] .
An improvement on these models is the CDX2 promoter-Cre mouse whose transgene expression is seen only in cecum, colon, and distal ileum of adult mice. When it is used to delete a floxed Apc allele, tumors form in the ileum and distal colon [28] . Unfortunately, transient expression of the CDX2-Cre transgene during embryonic development causes recombination of floxed alleles throughout the distal half of the body. This could reduce the utility of the CDX2-Cre model for many genes whose functions are present outside the colon. A tamoxifen-inducible version of this model, CDX2-CreER T2 , avoids the problem of embryonic transgene recombination [27] . However, the induced transgene activity is much higher in proximal colon than in the distal colon so its utility may be limited.
Our original CAC model [13] has a major advantage over the other models just described-intestinal transgene expression is specific to the large intestine. This makes the model useful to study the role of specific genes in basic colonic biology and in cancer. A weakness of the CAC model is that CAC transgene expression affects just a small portion of the colonic epithelium and extends to the crypt base mostly in the distal colon. Here we report a major advance for the CAC mouse-that Cre-mediated recombination is induced during DSS-mediated epithelial damage in the colon. The effect of DSS-induced colitis on CAC transgene activity occurs to a comparable degree in both the proximal colon and distal colon. The DSS/CAC model also has the advantage that the increase in transgene activation is directly related to the dose of DSS used but that increase does not involve the entire mucosa. For example, we found that only 40-50 % of the epithelial surface in the distal colon became transgene positive after treating mice with 2 % DSS for 5 days. Thus, in this model, both normal tissue (without transgene expression) and tissue with recombined alleles will be adjacent to one another. This will reduce the biological variation caused by intra-animal differences by providing an internal control for paired analysis of treatment effects.
An obvious use of the DSS/CAC model is to delete cancer-relevant genes and assess their impact on inflammation-induced colon cancer. As a preliminary test of this application, the DSS/CAC model was used to delete Apc gene alleles in the context of DSS-induced colitis. We found that in CAC mice with one inactivated Apc allele, DSS increased colonic tumor incidence fourfold (to 78.9 %) and tumor number per mouse threefold (to 4.5 colonic tumors per mouse). While this revealed the utility of our model, it also revealed a segment-specific risk of colon cancer. Despite the fact that DSS induces recombination of floxed alleles equally in both proximal colon and distal colon, tumors formed predominantly in the distal colon. This suggests that the different environmental influences interact with inflammation and Apc allele loss to affect cellular transformation and tumor development in the proximal and distal colon.
Several other applications for the new DSS/CAC model could also benefit the colon cancer or IBD research community. First, since the CAC transgene is activated in epithelial cells during active colitis, our model could provide insight into the epithelial role of specific genes during active inflammatory bowel disease and during the epithelial healing response. For example, several novel genes have been proposed to influence colitis and colitis-induced colon cancer through their impact on mucosal healing (e.g., NLRP6, TLR9, JAK3, FAK) [29] [30] [31] [32] . However, most of those genes are expressed in multiple cell types within the colon inflammatory microenvironment (e.g., NLRP6 is expressed in epithelial cells as well as macrophages, T cells, and B cells [33] ). Because of this, the results from studies with global gene deletion models are confounded, but the DSS/CAC model will allow one to overcome this problem and target the gene disruption directly to the site of ulceration and epithelial healing. Second, our model may allow researchers to examine the importance of specific genes in field cancerization [34] [35] [36] . This concept suggests that the cancer development starts in relatively large areas of tissue due to early protumorigenic alternations. These mutations may not be sufficient to cause cancer, but they predispose the tissue to further cancer-causing mutations. The molecular alterations that create a field or push a field toward cancer can be induced by microenvironmental triggers like colonic inflammation. For example, multiple bouts of tissue damage and repair in IBD patients increase colon cancer risk [37] . In patients with ulcerative colitis who have developed neoplasia, TP53 or KRAS mutations can be detected in both the neoplastic area and non-dysplastic crypts [38] . This suggests that the mutated cells had populated a large field of mucosa prior tumor formation. Our DSS/CAC model can be used to generate a widespread field cells with specific gene mutations in the colon.
In summary, we observed a novel phenotype for the CAC model-that the Cre transgene-mediated recombination is induced following DSS treatment. This opens the opportunity to study gene function at the time of colitis development as well as after the recovery of colitis. We believe the DSS/ CAC model is an efficient, reliable model for research on the epithelial cell biology of colitis and inflammation-induced colon cancer. This will make the CAC/DSS model a powerful tool to study the mechanisms by which inflammation alters the colonic epithelium (including cellular transformation) as well as to assess interventions to minimize the impact of inflammation on colonic diseases.
